Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 9/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977698 | 0.87 | FAAH (0.48) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL27654953 | 0.86 | CHRM4 (0.42) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2967121 | 0.86 | KDM4E (0.52) | CHRM4FAAHACHE | |
| SCHEMBL2967113 | 0.85 | CHRM4 (0.54) | CHRM4ACHE | |
| SCHEMBL3937764 | 0.85 | CHRM4 (0.57) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2974298 | 0.83 | CHRM2 (0.58) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2974765 | 0.81 | CHRM4 (0.45) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2976065 | 0.81 | CHRM4 (0.56) | CHRM4CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL2971277 | 0.81 | FAAH (0.48) | CHRM4FAAHACHE | |
| SCHEMBL2977318 | 0.81 | ACHE (0.52) | CHRM4FAAHACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| US-7781590-B2 | Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| CN-1921858-A | Piperidinylalkylcarbamate derivatives, process for their preparation and their use as FAAH enzyme inhibitors | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | CN | disclosed |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | CHRM4 2647/4885CHRM2 3417/4885CHRM5 2491/4885 |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | CHRM4 2788/4885CHRM2 3665/4885CHRM5 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.